Evidence map›Paper›PMID 40792500›Full record

ArticleMicrobiology spectrum2025

Performance of novel digital real-time PCR for detection of SARS-CoV-2, respiratory syncytial viruses, and influenza viruses in Ghana.

Michael Owusu, Bernard Nkrumah, Godfred Acheampong, Stephen Opoku Afriyie, Ebenezer Kojo Addae, Richard Larbi, Richard Owusu Ansah, Chrysantus Kubio, Farouk Saeed, Nana Kwame Ayisi-Boateng and 8 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michael OwusuCentre for Health System Strengthening, Kumasi, Ghana.ORCID 0000-0001-5066-150X
Bernard NkrumahAfrican Field Epidemiology Network, Accra, Ghana.
Godfred AcheampongCentre for Health System Strengthening, Kumasi, Ghana.
Stephen Opoku AfriyieCentre for Health System Strengthening, Kumasi, Ghana.ORCID 0000-0002-8334-5332
Ebenezer Kojo AddaeCentre for Health System Strengthening, Kumasi, Ghana.ORCID 0009-0004-3999-170X
Richard LarbiGenomic and Infectious Disease Laboratory, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Richard Owusu AnsahGenomic and Infectious Disease Laboratory, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Chrysantus KubioRegional Health Directorate, Ghana Health Service, Savannah, Ghana.
Farouk SaeedRegional Health Directorate, Ghana Health Service, Savannah, Ghana.
Nana Kwame Ayisi-BoatengUniversity Health Services, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Eric DarkoUniversity Health Services, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Jacob Amonoo-NeizerDepartment of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Abena Gyawu Owusu-AnsahHopeXchange Medical Centre, Kumasi, Ghana.
Frederick AyensuHopeXchange Medical Centre, Kumasi, Ghana.
Peter Kojo BrenyaHopeXchange Medical Centre, Kumasi, Ghana.
Veronica BannorAsokwa Children's Hospital, Kumasi, Ghana.
Pawan AngraDivision of Global Health Protection, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Danielle Thompson BarradasDivision of Global Health Protection, Global Health Center, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

CGH CDC HHS U19 GH000041US Center for Disease Control and Korean International Cooperation Agency NU2HGH000041-02-00
6 · The paper itself

Abstract

Digital PCR (dPCR) systems offer high sensitivity and reproducibility without requiring external control standards. However, their performance against real-time reverse transcription-PCR (rRT-PCR) for detecting respiratory viruses remains unexplored in Ghana. We therefore evaluated the performance of a novel dPCR, Lab-On-An-Array (LOAA), for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), respiratory syncytial virus (RSV), and influenza viruses type A (Flu A) and B (Flu B). A cross-sectional hospital-based study was conducted between August 2022 and January 2023 in Ghana's Ashanti and Savannah Regions. Oropharyngeal swabs from 356 participants with a median age of 19 years, presenting with suspected respiratory illness, were tested using LOAA and rRT-PCR. Viral RNA was extracted using a Qiagen Viral Mini Kit (Qiagen Diagnostics GmbH, Germany). LOAA and rRT-PCR tests were performed using Genoplexor COVID-19/Flu/RSV Detection Kit (Optolane Technologies Inc, South Korea) and FluoroType SARS-CoV-2/Flu/RSV kits (Hain Lifescience GmbH, Germany), respectively. LOAA's performance metrics were assessed using rRT-PCR as the gold standard. Overall positivity rates were 29.78% and 30.90% for LOAA and rRT-PCR, respectively. Compared to rRT-PCR, LOAA's sensitivity was 87.76% for RSV, 91.30% for SARS-CoV-2, 86.21% for Flu B, and 88.89% for Flu A. Positive predictive value was the highest for RSV (97.73%) and lowest for Flu A (61.54%); negative predictive values were ≥98.00% for all respiratory viruses. LOAA recorded an "almost perfect" agreement (κ ≥0.88) with rRT-PCR for RSV, SARS-CoV-2, and Flu B and good agreement for Flu A (κ = 0.72). LOAA is sensitive in detecting SARS-CoV-2, RSV, and Flu B infections; however, minor improvements for Flu A are required. IMPORTANCE: This study presents the potential of a digital PCR as a highly sensitive and reproducible tool for detecting respiratory viruses in Ghana, where robust diagnostic methods are essential for managing public health challenges. By evaluating the novel Lab-On-An-Array (LOAA) system, we provide its critical operational performance against the gold-standard rRT-PCR for detecting severe acute respiratory syndrome coronavirus 2, respiratory syncytial virus, and influenza viruses. Our findings show that LOAA demonstrates excellent agreement with rRT-PCR for most viruses, offering a promising alternative for respiratory virus surveillance and diagnosis. This research is particularly significant for resource-limited settings, as it supports the adoption of advanced molecular diagnostics to improve early detection and response to respiratory infections. Minor refinements for specific viruses, such as influenza A, could further enhance its utility in clinical and epidemiological applications.

Indexed as

COVID-19Influenza, HumanReal-Time Polymerase Chain ReactionRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsSARS-CoV-2AdolescentAdultAgedChildChild, PreschoolCross-Sectional StudiesFemaleGhanaHumansInfantRNA, ViralGhanainfluenzaLab On An Arrayrespiratory virusesRSVRT-PCRSARS-CoV-2

Identifiers

PMID40792500
PMCPMC12403756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.